Effect of mi-138 targeting PLD2 gene on proliferation and migration of oral cancer cells

doi:10.19439/j.sjos.2020.01.005

Abstract

Abstract: PURPOSE: To investigate the effect of miR-138 targeting PLD2 gene on proliferation and migration of oral cancer cells. METHODS: After oral cancer cells were transfected with miR-138, the expression level of microRNA-138 was detected by RT-PCR assay, the proliferation ability was detected by MTT assay, and cell cycle distribution was detected by flow cytometry. Transwell migration assay was used to detect cell migration ability, Western blotting assay was used to detect the expression levels of MMP-9, PLD2 and cyclin D1 in gastric cancer cells. Luciferase assay was used to report the targeting relationship between microRNA-138 and PLD2 gene. SPSS 21.0 software package was used to analyze the data. RESULTS: After miR-138 was transfected into oral cancer cells, the relative expression level of miR-138 was 4.28±; 0.16, which was significantly higher than that of blank control and miR-NC group (P<; 0.05). Luciferase reporter gene assay showed that the relative activity of PLD2 wild plasmid luciferase was significantly lower in oral cancer cells transfected with microRNA-138 than in other groups (P<; 0.05); The expression level of PLD2 gene in miR-138 group was significantly lower than that in blank control group and miR-NC group (P<; 0.05). After oral cancer cells were transfected with miR-138, the proliferation ability of oral cancer cells in miR-373 group was significantly lower than that in control group and miR-NC group (P<; 0.05). Flow cytometry showed that the ratio of G₀/G₁ phase was (64.39±; 6.49)% in the group of miR-138, which was significantly higher than that in the blank control group and the group of miR-NC(P<; 0.05); The ratio of S phase in the group of miR-138 was(13.28±; 3.16)%, which was significantly lower than that in the blank control group and the group of miR-NC (P<; 0.05); There was no significant difference in the ratio of G₂/M phase among the groups (P>; 0.05). Transwell experiment showed that the number of migrating cells transfected with miR-138 in oral cancer cells was 138.46±; 24.37, which was significantly lower than that in blank control group and miR-NC group(P<; 0.05). Western blotting experiments showed that the relative levels of MMP-9, vimentin and cyclin D1 in the miR-138 group were 0.14±; 0.04, 0.17±; 0.02 and 0.15±; 0.03, respectively, which were significantly lower than those in the blank control group and the miR-NC group(P<; 0.05). CONCLUSIONS: miR-138 can target PLD2 gene expression and inhibit the proliferation and migration of oral cancer cells.

Key words: MiR-138, Oral cancer, PLD2 gene, Proliferation, Migration

CLC Number:

R739.8

LI Huai-qi, YE Jin-hai, DING Xu, WU He-ming. Effect of mi-138 targeting PLD2 gene on proliferation and migration of oral cancer cells[J]. Shanghai Journal of Stomatology, 2020, 29(1): 25-30.

References

[1] 王璇, 闫妍, 高山, 等. 血浆miRNA-486-5p作为口腔鳞癌复发标志物的临床研究[J]. 中华老年口腔医学杂志, 2018, 16(3): 142-146.
[2] Wang J, Li L, Gao L, et al.Identification of differentially expressed genes in oral squamous cell carcinoma TCA8113 cells[J]. Oncol Lett, 2017, 14(6): 7055-7068.
[3] Chen Z, Li D, Cheng Q, et al.MicroRNA-203 inhibits the proliferation and invasion of U251 glioblastoma cells by directly targeting PLD2[J]. Mol Med Rep, 2014, 9(2): 503-508.
[4] 李怀奇, 武和明, 丁旭, 等. HPV16E6与抑癌基因p53在口腔癌中的表达及临床意义[J]. 上海口腔医学, 2017, 26(6): 615-618.
[5] Thomas N, Krishnapillai R, Bindhu PR.Immunohistochemical expression of cyclooxygenase-2 in oral squamous cell carcinoma[J]. Indian J Dent Res, 2019, 30(1): 102-106.
[6] Grimes JA, Mestrinho LA, Berg J, et al.Histologic evaluation of mandibular and medial retropharyngeal lymph nodes during staging of oral malignant melanoma and squamous cell carcinoma in dogs[J]. J Am Vet Med Assoc, 2019, 254(8): 938-943.
[7] Ainapur MMAR, Mahesh P, Kumar K, et al.An in vitro study of isolation of candidal strains in oral squamous cell carcinoma patients undergoing radiation therapy and quantitative analysis of the various strains using CHROMagar[J]. J Oral Maxillofac Pathol, 2017, 21(1): 11-17.
[8] Yan G, Wang X, Yang M, et al.Long non-coding RNA TUG1 promotes progression of oral squamous cell carcinoma through upregulating FMNL2 by sponging miR-219[J]. Am J Cancer Res, 2017, 7(9): 1899-1912.
[9] Feng J, Xu J, Xu Y, et al.CLIC1 promotes the progression of oral squamous cell carcinoma via integrins/ERK pathways[J]. Am J Transl Res, 2019, 11(2): 557-571.
[10] Tsuchiya Y, Ushijima K, Noguchi T, et al.Influence of a dosing-time on toxicities induced bydocetaxel, cisplatin and 5-fluorouracil in patients with oral squamous cell carcinoma; a cross-over pilot study[J]. Chronobiol Int, 2018, 35(2): 289-294.
[11] 王丽萍, 郭雪琪, 闫勇勇, 等. miR-146a在口腔鳞癌组织及细胞中的表达及功能研究[J]. 口腔医学研究, 2017, 33(11): 1204-1208.
[12] Ye Z, Fang B, Pan J, et al.miR-138 suppresses the proliferation, metastasis and autophagy of non-small cell lung cancer by targeting Sirt1[J]. Oncol Rep, 2017, 37(6): 3244-3252.
[13] Hong Y, He H, Sui W, et al.Long non-coding RNA H1 promotes cell proliferation and invasion by acting as a ceRNA of miR 138 and releasing EZH2 in oral squamous cell carcinoma[J]. Int J Oncol, 2018, 52(3): 901-912.
[14] 黄文曦, 欧阳颖, 魏常博, 等. 舌鳞状细胞癌细胞株CAL27外泌体源性miR-21、miR-221和miR-222的表达[J]. 口腔疾病防治, 2018, 26(4): 222-226.
[15] Luo YD, Ding X, Du HM, et al.FOXM1 is a novel predictor of recurrence in patients with oral squamous cell carcinoma associated with an increase in epithelial mesenchymal transition[J]. Mol Med Rep, 2019, 19(5): 4101-4108.
[16] 李雨辰, 李寒, 陈世璋. Notch基因在口腔癌和癌前病变患者癌组织及癌旁组织中的表达[J]. 临床和实验医学杂志, 2018, 17(21): 2284-2288
[17] Juneja S, Katyal S, Rathore AS, et al.Utility of DNA-Specific stains in micronuclei assay as a marker of genotoxicity in oral potentially malignant disorders and oral squamous cell carcinoma[J]. J Cytol, 2019, 36(2): 111-115.
[19] Abe Y, Ogasawara S, Akiba J, et al.Expression and role of regulator of G-protein signaling 5 in squamous cell carcinoma of the tongue[J]. Clin Exp Dent Res, 2019, 5(2): 160-169.
[20] Belusic-Gobic M, Zubovic A, Cerovic R, et al.Multivariate analysis of risk factors for postoperative wound infection following oral and oropharyngeal cancer surgery[J]. J Craniomaxillofac Surg, 2018, 46(1): 135-141.
[21] Wang X, Gu J, Shao C, et al.Nimotuzumab plus chemotherapy with docetaxel, cisplatin, 5-fluorouracil for locally advanced head and neck squamous cell carcinoma: A clinical study[J]. J Cancer Res Ther, 2019, 15(2): 312-316.
[22] Datta S, Mishra A, Chaturvedi P, et al.Frozen section is not cost beneficial for the assessment of margins in oral cancer[J]. Indian J Cancer, 2019, 56(1): 19-23.
[23] Anusa AM, Thavarajah R.Risk of cognition alteration and emotional frailty via circulating transcriptome in treatment naive head and neck squamous cell cancer patients[J]. J Oral Biol Craniofac Res, 2019, 9(2): 143-150.